Skip to main content

Advertisement

SpringerLink
Log in

Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the treatment outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRVO).

Methods

A prospective interventional study was conducted in a tertiary retina service in Leicester Royal Infirmary, UK, where patients with CRVO and associated macular oedema were recruited. First-line treatment involved three monthly ranibizumab injections. Non-responders were defined as patients who despite a minimum of three consecutive injections had persistent intraretinal fluid one month after the last injection. In these cases, a treatment change to aflibercept injections on a per-needed basis was decided. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and after switching of treatment. Follow-up period lasted for a minimum of 24 weeks after switching.

Results

Twenty-nine eyes of 29 patients with refractory macular oedema secondary to CRVO were included. All eyes had an average of 4.5 ranibizumab intravitreal injections in a mean period of 6 months without reduction in intraretinal fluid and/or no visual acuity gain. A significant decrease in mean CRT from 633.67 ± 242.42 to 234.62 ± 78.28 μm and improvement in mean BCVA from 1.34 ± 0.66 log MAR to 0.91 ± 0.73 log MAR were noticed after switching treatment to aflibercept. The average number of aflibercept injections needed for oedema resolution was 2.19.

Conclusions

Aflibercept is an effective alternative treatment for macular oedema secondary to CRVO refractory to ranibizumab. Good anatomical and functional result can be achieved with few injections. The maintenance of these results after 6 months is yet to be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond) 25:981–988

    Article  CAS  Google Scholar 

  2. Miller JW, Le Couter J, Strauss EC, Ferrara N (2013) Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120:106–114

    Article  PubMed  Google Scholar 

  3. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB (2014) Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 5:CD007325. doi:10.1002/14651858.CD007325.pub3

    PubMed Central  Google Scholar 

  4. Ford JA, Clar C, Lois N, Barton S, Thomas S, Court R, Shyangdan D, Waugh N (2014) Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open 4:e004120. doi:10.1136/bmjopen-2013-004120

    Article  PubMed  PubMed Central  Google Scholar 

  5. Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 1:8–15. doi:10.1159/000315155

    Article  Google Scholar 

  6. Rezar-Dreindl S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Dunavölgyi R, Weigert G, Kroh ME, Schmidt-Erfurth U, Sacu S (2016) Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol. doi:10.1111/aos.13152

    PubMed  Google Scholar 

  7. Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491

    Article  Google Scholar 

  8. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133

    Article  PubMed  Google Scholar 

  9. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. doi:10.1016/j.ophtha.2011.12.005

    Article  PubMed  Google Scholar 

  10. Campochiaro P, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219. doi:10.1016/j.ophtha.2013.08.038

    Article  PubMed  Google Scholar 

  11. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420

    Article  PubMed  Google Scholar 

  12. Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, GALILEO Study Group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038

    Article  CAS  PubMed  Google Scholar 

  13. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93:452–456

    Article  CAS  PubMed  Google Scholar 

  14. Zhang H, Liu Z, Sun P, Gu F (2011) Intravitreal bevacizumab for treatment of macular edema secondary to retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27:615–621

    Article  CAS  PubMed  Google Scholar 

  15. Aslankurt M, Aslan L, Aksoy A, Erden B, Cekic O (2013) The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 23:553–557

    Article  PubMed  Google Scholar 

  16. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15–22

    Article  CAS  PubMed  Google Scholar 

  17. Batioglu F, Demirel S, Ozmert E, Abdullayev A, Bilici S (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmol 15:40

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hanhart J, Chowers I (2015) Evaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edema. Case Rep Ophthalmol 6:44–50

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL (2015) Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) 29:534–541

    Article  CAS  Google Scholar 

  20. Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM, Wu D, Young LH, Kim IK, Vavvas DG, Esmaili DD, Husain D, Eliott D, Kim LA (2016) Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond) 30:79–84

    Article  CAS  Google Scholar 

  21. Eadie JA, Ip MS, Kulkarni AD (2014) Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina 34:2439–2443

    Article  CAS  PubMed  Google Scholar 

  22. Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A (2015) The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd 232:552–555

    Article  CAS  PubMed  Google Scholar 

  23. Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J, Chiang A (2016) Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 51:342–347

    Article  PubMed  Google Scholar 

  24. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG (2013) Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 120:1057–1063

    Article  PubMed  Google Scholar 

  25. Ashraf M, Souka AA, Singh RP (2016) Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond) 30:505–514

    Article  CAS  PubMed Central  Google Scholar 

  26. Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J (2016) The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmol 94(5):e353–e355. doi:10.1111/aos.12832

    Article  PubMed  Google Scholar 

  27. Daien V, Navarre S, Fesler P, Vergely L, Villain M, Schneider C (2012) Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 22:1013–1018

    Article  PubMed  Google Scholar 

  28. Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S (2015) Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res 54:150–156

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leicester Royal Infirmary, University Hospitals of Leicester, Infirmary Square, Leicester, LE1 5WW, UK

    Vasileios Konidaris, Zahra Al-Hubeshy, Konstantinos T. Tsaousis, Konstantina Gorgoli, Somnath Banerjee & Theodoros Empeslidis

Authors
  1. Vasileios Konidaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahra Al-Hubeshy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantinos T. Tsaousis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Konstantina Gorgoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Somnath Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theodoros Empeslidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasileios Konidaris.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Konidaris, V., Al-Hubeshy, Z., Tsaousis, K.T. et al. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab. Int Ophthalmol 38, 207–213 (2018). https://doi.org/10.1007/s10792-017-0512-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-017-0512-8

Keywords

Search

Navigation